Investors / filer profile

Urist Marshall

EVP, Research & Investments

active in 1 company

Pro
Bought: Pro
Sold: 19
Filings: 1
Companies: 2026-08-05
Last filed

EDGAR · CIK 0001838139 ↗

Track record

How each disclosed position did against the S&P ~6 months later

No positions we can measure against the market yet — outcomes appear once a disclosed buy is ~6 months old.

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

Activity

Open-market buy & sell volume

BuySell

Total +$0.0000 bought · −$10.83M sold

All filings on record

Every Form 4 transaction we track for this filer


RPRXRoyalty Pharma plc	Grant — · 8,252 sh	2026-08-05	—
RPRXRoyalty Pharma plc	Sell $502.1K · 9,098 sh	2026-06-24	—
RPRXRoyalty Pharma plc	Sell $721.8K · 13,684 sh	2026-05-20	—
RPRXRoyalty Pharma plc	Grant — · 19,970 sh	2026-02-11	—
RPRXRoyalty Pharma plc	Sell $821.8K · 20,000 sh	2026-01-30	—
RPRXRoyalty Pharma plc	Sell $805.1K · 20,000 sh	2026-01-23	—
RPRXRoyalty Pharma plc	Sell $790.3K · 20,000 sh	2026-01-16	—
RPRXRoyalty Pharma plc	Sell $815.6K · 20,000 sh	2026-01-09	—
RPRXRoyalty Pharma plc	Sell $769.6K · 20,000 sh	2026-01-02	—
RPRXRoyalty Pharma plc	Sell $786.4K · 20,000 sh	2025-12-26	—

RPRXGrant

2026-08-05 · Royalty Pharma plc

8,252

—

RPRXSell

2026-06-24 · Royalty Pharma plc

$502.1K

—

RPRXSell

2026-05-20 · Royalty Pharma plc

$721.8K

—

RPRXGrant

2026-02-11 · Royalty Pharma plc

19,970

—

RPRXSell

2026-01-30 · Royalty Pharma plc

$821.8K

—

RPRXSell

2026-01-23 · Royalty Pharma plc

$805.1K

—

RPRXSell

2026-01-16 · Royalty Pharma plc

$790.3K

—

RPRXSell

2026-01-09 · Royalty Pharma plc

$815.6K

—

RPRXSell

2026-01-02 · Royalty Pharma plc

$769.6K

—

RPRXSell

2025-12-26 · Royalty Pharma plc

$786.4K

—

Newest 10 of 19 filingsEvery Form 4 on record, with outcomesPro →

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.